Sutro Biopharma (STRO) Stock Statistics & Valuation Metrics

Sutro Biopharma has a market cap or net worth of $68.02M. The enterprise value is $74.93M.

Sutro Biopharma has 84,461,365 shares outstanding. The number of shares has decreased by -2.65% in one year.

Sutro Biopharma’s return on equity (ROE) is -5.10 and return on invested capital (ROIC) is -91.69%.

The current PE Ratio of Sutro Biopharma is ―. Sutro Biopharma’s PEG ratio is ―.

In the last 12 months, Sutro Biopharma had revenue of 62.04M and earned -227.46M in profits. Earnings per share was -2.96.

In the last 12 months, operating cash flow was -194.68M and capital expenditures -3.83M, giving a free cash flow of -198.51M billion.

Sutro Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―

Sutro Biopharma upcoming earnings date is Nov 5, 2025, TBA (Confirmed).

Sutro Biopharma as a current ratio of 2.60, with Debt / Equity ratio of -82.90%

In the past 12 months, Sutro Biopharma has paid 2.36M in taxes.

Sutro Biopharma EV to EBITDA ratio is 0.14, with an EV/FCF ratio of 0.13.

Sutro Biopharma has $248.97M in cash and marketable securities with $21.40M in debt, giving a net cash position of -$227.57M billion.

Gross margin is 3.83%, with operating margin of -384.34%, and net profit margin of -366.62%.

The average price target for Sutro Biopharma is $1.60, which is 11.43% higher than the current price. The consensus rating is Hold